Metabolomics reveals the potential metabolic mechanism of infliximab against DSS-induced acute and chronic ulcerative colitis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Metabolomics reveals the potential metabolic mechanism of infliximab against DSS-induced acute and chronic ulcerative colitis

Published:2024-06-07 Issue: Volume: Page:
ISSN:0028-1298
Container-title:Naunyn-Schmiedeberg's Archives of Pharmacology
language:en
Short-container-title:Naunyn-Schmiedeberg's Arch Pharmacol

Author:

Zhong Guoqiang,Shi Runjie,Chen Qiusan,Zheng Yifeng,Fan Xiujing,Sun Yan,Wang Shanping,Li Mingsong

Funder

Basic and Applied Basic Research Foundation of Guangdong Province

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00210-024-03201-9.pdf

Reference47 articles.

1. Abdelrahman AM, Al Suleimani YM, Manoj P, Ashique M, Ali BH, Schupp N (2020) Effect of infliximab, a tumor necrosis factor-alpha inhibitor, on doxorubicin-induced nephrotoxicity in rats. Naunyn Schmiedebergs Arch Pharmacol 393:121–130. https://doi.org/10.1007/s00210-019-01719-x

2. Abraham C, Dulai PS, Vermeire S, Sandborn WJ (2017) Lessons learned from trials targeting cytokine pathways in patients with inflammatory bowel diseases. Gastroenterology 152(2):374–388e374. https://doi.org/10.1053/j.gastro.2016.10.018

3. Adolph TE, Meyer M, Schwärzler J, Mayr L, Grabherr F, Tilg H (2022) The metabolic nature of inflammatory bowel diseases. Nat Reviews Gastroenterol Hepatol 19(12):753–767. https://doi.org/10.1038/s41575-022-00658-y

4. Afonso MB, Rodrigues PM, Mateus-Pinheiro M, Simão AL, Gaspar MM, Majdi A, Arretxe E, Alonso C, Santos-Laso A, Jimenez-Agüero R (2021) RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease. Gut 70(12):2359–2372. https://doi.org/10.1136/gutjnl-2020-321767

5. Aldars-García L, Gil-Redondo R, Embade N, Riestra S, Rivero M, Gutiérrez A, Rodríguez-Lago I, Fernández-Salazar L, Ceballos D, Manuel Benítez J (2023) Serum and urine metabolomic profiling of newly diagnosed Treatment-Naïve inflammatory bowel Disease patients. Inflamm Bowel Dis izad154. https://doi.org/10.1093/ibd/izad154

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3